Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.